AstraZeneca enters agreement with IntelliCyt to develop high throughput biology applications
May 10, 2016 – ALBUQUERQUE. IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery and immuno-oncology research today announced a collaboration with AstraZeneca to further the development of high throughput biology applications to provide insights into the complex biology of disease. AstraZeneca will utilize IntelliCyt products to profile phenotypic and functional endpoints of cells through the use of cell-based and bead-based assays in AstraZeneca’s advanced phenotypic drug discovery and immune-profile programs.
The ability to better understand the biological mechanisms of disease earlier in the drug discovery process will lower cost, improve lead selection and ultimately result in better, safer more efficacious drugs. The IntelliCyt iQue® Screener platform, an integrated instrument, software and reagent system, offers proprietary high throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96, 384, and 1536 well plates. In addition to the fastest plate processing speed in the industry today for this type of analysis, miniaturization of the assay is possible to save reagent cost and conserve precious samples. Additionally, high content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system. Data analysis and visualization using ForeCyt® software, provides unique insights into the complex biology of disease.
“With our proprietary multiplexed cell-based and bead-based analytics platform, we provide deeper insight into cellular function early in the discovery process,” said Janette Phi, Chief Business Officer of IntelliCyt. “We are excited to collaborate with AstraZeneca in demonstrating the utility of our iQue Screener technologies for the discovery of novel drug candidates.”
“We are very pleased to be working with IntelliCyt in this collaborative way. We have demonstrated the impact this technology can have in our hit finding capability and this collaboration will insure that we continue to develop what is an exciting and important technology for us,” said Dr. Steve Rees AstraZeneca, Screening Sciences Vice President.